Natera to Present 14 Studies at ESMO, Including IMvigor011 Oral Presentation in Presidential Symposium

Natera will present 14 studies at the European Society for Medical Oncology (ESMO) Congress 2025, including six oral presentations highlighting the Signatera assay’s expanding use in solid tumors111.

The IMvigor011 phase III trial in muscle-invasive bladder cancer (MIBC), sponsored by Genentech, has been selected for the Presidential Symposium on October 20, 2025, at ESMO1.

IMvigor011 is the first prospective phase III study in MIBC to use a bespoke molecular residual disease (MRD) guided approach with Signatera, showing it can predict disease-free and overall survival benefits from adjuvant Tecentriq (atezolizumab)1.

Natera's presentations cover diverse cancer types including bladder, colorectal, and breast cancer, demonstrating the growing impact of personalized MRD assessment for treatment and monitoring18.

A separate investor call will be hosted by Natera on October 23, 2025, to discuss key ESMO findings, focusing on IMvigor011 and CheckMate 274 trials in bladder cancer3.

Sources:

1. https://www.natera.com/company/news/natera-to-present-14-studies-at-esmo-including-imvigor011-oral-presentation-in-presidential-symposium/

3. https://www.businesswire.com/news/home/20251013338031/en/Natera-to-Host-Investor-Call-on-October-23-2025-to-Discuss-ESMO-Findings

8. https://www.natera.com/company/news/signatera-data-from-i-spy-2-trial-to-be-presented-at-esmo-breast-annual-congress/

11. https://www.tradingview.com/news/reuters.com,2025:newsml_FWN3VR2VF:0-natera-says-to-present-14-studies-at-esmo-including-imvigor011-oral-presentation/